AltPep Further Strengthens Advisory Board with Appointment of Steven E. Kahn, M.B., Ch.B.

SEATTLE–()–AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced the appointment of Steven E. Kahn, M.B., Ch.B. to its Advisory Board. The Advisory Board consists of world-renowned experts in discovery, preclinical and clinical research in Alzheimer’s disease, other neurodegenerative disorders and now diabetes.

“We are thrilled to add Dr. Kahn’s deep clinical and research experience to our Advisory Board,” said Valerie Daggett, Ph.D., Founder and CEO of AltPep. “His expertise in Type 2 diabetes will be integral as we plan for the extension of our platform beyond neurodegenerative disorders. Further, because there is growing evidence to support a link between Type 2 diabetes and dementia, Dr. Kahn’s in-depth knowledge of this patient population will have broad applicability to AltPep’s programs. Together with the contributions of our current advisors, Dr. Kahn’s extensive research skills will be vital as we advance our Alzheimer’s and Parkinson’s disease programs into the clinic next year.”

Steven E. Kahn, M.B., Ch.B., is a Professor of Medicine at the University of Washington (UW), Director of the UW Diabetes Research Center and is also a clinician at the VA Puget Sound Health Care System. An expert in Type 2 diabetes, Dr. Kahn continues to participate in some of the major NIH clinical studies examining the pathophysiology, prevention and treatment of Type 2 diabetes. He has received numerous awards for his research, some of which include The Endocrine Society Clinical Investigator Award, Department of Veterans Affairs John B. Barnwell Award, European Association for the Study of Diabetes Albert Renold Award, and American Diabetes Association Outstanding Achievement in Clinical Diabetes Research Award.

Dr. Kahn joins the existing advisory board members: Paul Aisen, M.D., Roger Armen, Ph.D., Sir Alan Fersht, Ph.D., Ronald DeMattos, Ph.D., Sam Gandy, M.D., Ph.D., Charles Glabe, Ph.D., Michael Levitt, Ph.D., and Jeff Roh, M.D., MBA, M.Sc. See our board here.

“The breath of AltPep’s platform is impressive,” said Dr. Kahn. “I am honored to be working with such a world-class group of scientists and advisors and am excited to contribute to the goal of making new diagnostic and treatment alternatives available for these devastating diseases.”

About AltPep’s SOBA Diagnostics and SOBIN Therapeutics

SOBIN therapeutics are in development for use in concert with early detection to target and neutralize the toxic soluble oligomers associated with amyloid diseases. SOBA diagnostics are highly sensitive, simple blood tests in development to aid in the diagnosis of amyloid diseases.

About AltPep Corporation

AltPep is developing groundbreaking disease-modifying treatments and detection tools for amyloid diseases by targeting early molecular triggers: toxic soluble oligomers. Our customized, synthetic peptides are designed to bind selectively to toxic oligomers in order to both detect and neutralize them throughout disease progression. AltPep’s emphasis is on early, pre-symptomatic detection and treatment. Our lead programs focus on Alzheimer’s and Parkinson’s diseases, with other amyloid diseases, such as Type 2 diabetes, on the horizon. AltPep’s goal is to change the course of these debilitating diseases that affect over a billion people around the globe.

Decades of scientific research by the Daggett Research Group at the UW provided the foundation for AltPep’s innovative approach.

For more information, please visit and follow us on LinkedIn.


Recent Articles